Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2011 by Innovative Medical.
Recruitment status was:  Recruiting
Information provided by:
Innovative Medical Identifier:
First received: January 14, 2011
Last updated: February 16, 2011
Last verified: February 2011
The purpose of this study is to look at how well you see the Nanoflex Intraocular lens placed in your eye.

Condition Intervention Phase
Patients Who Have Bilateral NanoFlex Implantation at Least 3 Months Previously
Device: Nanoflex IOL
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses

Further study details as provided by Innovative Medical:

Primary Outcome Measures:
  • Uncorrected Near Visual Acuity [ Time Frame: 1 year ]

Estimated Enrollment: 100
Study Start Date: January 2011
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Nanoflex IOL Device: Nanoflex IOL
Patients who were implanted with the Nanoflex IOL


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female patients at least 18 years of age.
  • Patients who have bilateral NanoFlex implantation at least 3 months previously.
  • No significant ocular pathology causing DCVA to be less than 20/25 or causing significant visual loss.
  • DCVA of 20/25 or better in both eyes.
  • Spherical equivalent in the dominant eye to be +/-.50 or less and in the non-dominant eye to be between-1.00 and -1.87.
  • Uncorrected VA in dominant eye 20/25 or better.

Exclusion Criteria:

  • History of ocular trauma or prior ocular surgery (minor ocular trauma is allowed such as small superficial corneal scar not effecting vision; some prior ocular surgery is allowable so long as it has not impacted visual acuity.
  • Amblyopia or strabismus, significant visual field loss, or posterior capsular opacifcation.
  • Known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01279122

Contact: Annie Christensen 951-653-5566

United States, Virginia
Kenneth Lipstock Recruiting
Richmond, Virginia, United States
Contact: Annie Christensen    951-653-5566   
Sponsors and Collaborators
Innovative Medical
  More Information

Responsible Party: Annie Christensen, IMEDS Identifier: NCT01279122     History of Changes
Other Study ID Numbers: STARR2010-NF-IOL
Study First Received: January 14, 2011
Last Updated: February 16, 2011 processed this record on May 22, 2017